• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A novel antibiotic complex designated BBM-2478 is produced by fermentation of an actinomycete strain J907-21 (ATCC 39417). The complex may be separated chromatographically into two bioactive components designated BBM-2478A and BBM-2478B. The BBM-2478A component displays both antibacterial and antitumor activity while the BBM-2478B component has antibacterial activity.
    公开号:SU1423001A3
    申请号:SU843805267
    申请日:1984-10-02
    公开日:1988-09-07
    发明作者:Кониси Масатака；Сугавара Коко；Мияки Такео；Кавагути Хироси
    申请人:Бристоль-Мейерз Компани (Фирма)；
    IPC主号:
    专利说明:

    J
    This invention relates to the microbiological process and relates to the production of new glycosidic antibiotics that exhibit antibacterial activity against aerobic gram-positive and anaeronic bacteria, as well as antitumor activity.
    For the implementation of the method, strain 907-21 is used - unidentified asporogenic actinomycete.
    Cultural and morphological signs. Strain t 907-21 forms a long, well-branched vegetative ™ mycelium 0.4 µm wide, which is not divided into shelves or coccoid cells. On some I agar media, sometimes an octagonal short air mycelium, but a real aerial mycelium, sometimes forms , does not form on any of the described media. The spore-forming bodies and supports were not found.
    The cell membrane contains meso-diaminopimelic acid, and the cell hydrolyzate contains madurose, which allows the strain to be classified as type III cell membranes.





    The vulvar containing the trrutton and the yeast tract (isP No. 1) is a weak floccosis growth, pale yellow balls. Diffusing pigment is missing,
    Agar Chlpeka - no growth, 1-mysthelial mycelium from yellowish-white (92) to light olive, brown (94), Aerial mycelium is absent, there is no soluble pigment. Color and number in brackets corresponds to the standard of color on a scale of colors.
    Agar with glucose and asparagin is a weak growth. Substrate mycelium from Leltovato-white (92) to moderately olive, brown (95). Aerial mycelium is absent, soluble pigment is absent.
    Agar with inorganic salts and starch (ISP No. A) is weak, Substrate mycelium is grayish, yellowish, brown (80). Aerial mycelium is absent or very scarce, if a rudimentary Lseltovo-white (92) is formed, the first one (shgment is dark-gray, or | a) brown (81) "
    : 5-tyrosine agar (ISP I 7) - moderate growth. Substrate mycelium from
    2
    ten
    15
    20
    25
    50
    five
    g
    0
    ce1X) water yellow (90) to a bright yellow, brown (75). Aerial mycelium is absent, soluble pigment is absent.
    Nutrient agar is weak. Substrate mycelium from bright yellow (85) to dark olive, brown (96), Aerial mycelium is absent, there is no soluble pigment.
    Agar containing yeast extract and malt extract (ISP No. 2) is a measured growth. Substrate mycelium from yellowish-gray, yellow (91) to dark olive brown (96) Aerial mycelium is absent or very scarce, if it forms - a rudimentary, light grayish, yellowish, brown (79), soluble pigment is dark yellowish, brown ( 78).
    Oat flour agar (IGP 8 3) - moderate growth. Substrate mycelium varies from yellowish white (92) to greyish yellow (90). Aerial mycelium is absent, soluble pigment is absent.
    Agar Bennett - moderate growth. Substrate mycelium varies from dark gray, yellow (91) to dark olive, brown (96). Aerial mycelium is absent or very scarce if it forms - a rudimentary yellowish-white (92), soluble pigment bright yellow (85).
    Agar containing pentone, yeast extract, iron (ISP W 16) - moderate growth. Cyclical mycelium from light olive, brown (94) to bright yellow, brown (75). Aerial mycelium is absent. The soluble pigment is a brilliant orange-yellow (67).
    Agar VDYA - plentiful growth. Substrate mycelium from bright red (14) to blackish red (21), Aerial mycelium is absent. Soluble pigment dark red (16). I
    Cornmeal Agar - Growth
    abundant. Substrate mycelium from bright yellowish brown (75) to dark yellowish brown (78). Aerial mycelium is absent. Soluble pigment thick brown (55),
    Agar C-2 - growth is weak. Substrate mycelium is light yellowish, brown (75). Aerial mycelium ssut 1423001
    or very scanty if the media of the specified composition. Fermentation
    developed — rudimentary, white (263). carried out on a rotary vibrator. There is no soluble pigment. for 7–10 days, the contagar of potatoes and carrots is from moderate to moderate growth. Substrate mycelium from grayish-yellow (90) to temo-yellowish, brown (78). Aerial mycelium is absent. Soluble pigment temio-yellowish-pink (30).
    The colonies on ISP medium No. 2 are good, significantly swollen and multi-layered, 3-5 mm in diameter, the surface is reddish-black in color, the aerial mycelium does not form at all or a rudimentary aerial mycelium is formed.
    Data on cultural characteristics obtained after incubation at 28 ° C for 3 weeks.
    Physiological and biochemical properties. Maximum growth at 28 and 37 ° C. Does not grow at 7 and 45 ° C. Growth temperature range 15-43 ° C. Growth at pH 5.0 11.0, No growth at pH 4.5.
    Gelatin thins. KpaiiMan hydrates. Snoy milk does not coagulate, completely peptonizes. Melanoid
    g roller antibiotic activity using the Micrococcus luteus PCT 1001 test culture. The maximum antibiotic productivity is 150 µg / ml for 6-7 days of fermentation.
    10 Example 2. From a 20 liter culture liquid (pH 6.8), the mycelial cake was separated by centrifugation. The pellet of the mycelium is extracted 3 times in portions of 5 ml of methanol. The methanol extracts are filtered, combined and concentrated under vacuum to a water solution.
    The supernatant obtained after separation, separation of the mycelium, extracted with 20 l
    20 nb, utanola, and the extract is evaporated under vacuum to an aqueous solution.
    Two aqueous concentrates are combined and passed through a Diainon GC-20 column, eluted sequentially with 5 l.
    25 water, 5 liters of a 50% aqueous solution of methanol and 8 liters of an 80% aqueous solution of methanol.
    The fractions containing the BBM-2478 antibiotic complex are determined with
    pigments do not form. The reaction of tyrosis using the method of discs and test kush. Thiase is negative. Nitrates in nitrites do not restore. Sensitivity to NaCl grows with 4% NaCl and lower; it does not grow with 5% NaCl.
    Sensitive to lysozyme. No growth at 0.001% lysozyme.
    Utilization of carbohydrates. Utilizes glycerin, d (-) - arabiosis, 1 (+) - arabinose, d-cxIozy, d-ribose, Y.-raminosis, d-rJBftK03y, d-galactose, d-fructose, d-mannose, d-mannitol, salicin, cellobiose, tregose, does not utilize 1 (-) - sorbose, sucrose, lactose, melionosis, raffinose, d (+) - Me35
    Bacillus subtilis M45 (Rec.).
    The active fractions, eluted with 80% aqueous methanol, were collected, evaporated under reduced pressure and freeze dried. Obtain 4.5 g of a yellow solid - crude complex BBM-2478. The obtained substance is passed through a column of silica gel (3.5 x Q x 55 cm), previously with chloroform, and the active agent is eluted with a mixture of chlorophomethanol with a gradual increase in the concentration of methanol from 5 to 10% by volume. Perlesitose, cellulose, dulcite, inositol, active fraction, eloated
    d-sorbitol
    Example 1. A culture of strain 907-21 growing well on oblique agar was used for grafting a vegetative medium containing 3% soluble starch, 1% bacto-liver, 0.5% fish meal, 0.3% NaCl, 0.1% (NH4 ) aS04 and 0.6% CaCOj, pH 7.0, before sterilization; sreth Vegetative medium is incubated with during
    72 h on a rotary vibrator (250 rpm), and 5 ml cpeflj) i with culture are transferred to an 500 ml Erlenmeyer flask containing 100 ml of fermentation
    50
    55
    The 5% methanol solution is collected, concentrated under vacuum and lyophilized. 72 mg of BBM-2478B are obtained.
    The second active fraction, eluted with a 10% methanol solution, is processed in a similar manner. 2.51 g of semi-purified solid BBM-2478B are obtained. This material is subjected to subsequent chromatography on silica gel using medium pressure liquid chromatography. Chloroform: methanol (97: 3 v / v) is eluted. Acrolir is obtained for antibiotic activity using the Micrococcus luteus PCT 1001 culture test. The maximum antibiotic productivity is 150 µg / ml for 6-7 days of fermentation.
    Example 2. From a 20 liter culture liquid (pH 6.8), the mycelium pellet was separated by centrifugation. The pellet of the mycelium is extracted 3 times in portions of 5 ml of methanol. The methanol extracts are filtered, combined and concentrated under vacuum to a water solution.
    The supernatant obtained after separation, separation of the mycelium, extracted with 20 l
    nb, utanola, and the extract is evaporated under vacuum to an aqueous solution.
    Two aqueous concentrates are combined and passed through a Diainon GC-20 column, eluted sequentially with 5 l.
    water, 5 liters of a 50% aqueous solution of methanol and 8 liters of an 80% aqueous solution of methanol.
    The fractions containing the BBM-2478 antibiotic complex are determined with
    five
    Bacillus subtilis M45 (Rec.).
    The active fractions, eluted with 80% aqueous methanol, were collected, evaporated under reduced pressure and freeze dried. Obtain 4.5 g of a yellow solid - crude complex BBM-2478. The obtained substance is passed through a column of silica gel (3.5 x Q x 55 cm), previously with chloroform, and the active agent is eluted with a mixture of chlorophomethanol with a gradual increase in the concentration of methanol from 5 to 10% by volume. The first active fraction, eloirovannoe
    0
    five
    The 5% methanol solution is collected, concentrated under vacuum and lyophilized. 72 mg of BBM-2478B are obtained.
    The second active fraction, eluted with a 10% methanol solution, is processed in a similar manner. 2.51 g of semi-purified solid BBM-2478B are obtained. This material is subjected to subsequent chromatography on silica gel using medium pressure liquid chromatography. A mixture of chloroform: methanol (97: 3 v / v) is obtained; aq5 is obtained
    rich fractions that are concentrated under vacuum. A homogeneous -ergetic substance is obtained - 1.3 g of BBM-2A78A, it is crystallized from methanol, and yellow-orange needles of the BBM-2478A monohydrate are obtained
    Physico-chemical properties of antibiotics. Antibiotics BBM-2478 AiV yellowish-orange crystalline solids. VVM 2478A readily dissolves in dimethyl sulfoxide, dimethylformamide, donoxane, and acidified water, slightly soluble in methanol 9 ethanol and 5 O 4 form j practical 230016
    tically not soluble in other organic solvents. The solubility of the BBM-2478B is similar to the solubility of the A component, but not the solution — ccc in acidified water.
    Dauot antibiotics have positive reactions to iron (III) chloride and anthronic reagents. The reactions of Toller and Sakaguchi are negative.
    BBM-2478A gives a positive reaction to ninhydrin, B-component is negative. 15 Thin layer chromatography, R;

    Sioj
    CHClj-M H (7: 3) 0.37 Ol78
    BBM-2478A
    BBM-2478B


    Yellow
    Amorphous powder
    225-226
    Yellow
    Amor4 & 1st powder
    271-272 (with decomposition)
    -eight
    236 (740) 266 (700) 333 (118) 378 (169) 398 (255) 422 (290)
    NAO
    formula
    63.07
    4.51
    7в.цО (about
    63.16 4.48
    antibiotic
    Sio
    EtoAC-MeOH (1s1) 0.16 0.57
    25
    ° SN, YCHNO
    Structures 1 formula of the antibiotic BBM-2478B:
    BUT
    The biological properties (antibacterial activity) of the antibiotics BBM-2478 AiV are presented in the table.
    55
    The antibiotic BBM-2478A also has significant antitumor activity. Antitumor activity was determined in mice against LN4-PHYTIC leukemia P 388, lymphoid leukemia L. 1210 and melanotic melanoma B16.
    Formula inventions
    The method of producing glycosidic antibiotics BBM-2478A and BBM-2478B anti-tib "ethical complex BBM-2478 of the general formula HjC (BUT
    but
    ghh,
    t ±
    CHj
    about in
    where R is hydrogen (antibiotic BBM-2478B),
    or
    Rohj
    Htm
    axis.
    Microorganism type
    Staphylococcus aureus
    209r
    Staphylococcus aureus
    Smith
    Bacillus subtilia
    PCT 219.
    Micrococcus luteus
    PCT 1001
    Escherichia coli NIHJ micrococcus flavus D1
    Klebsiella pneumoniae dll
    Pseudomonas aeruginosa D15
    Candida albicans
    1AM 4888
    Cryptococcus neoformans D49
    (antibiotic FBM-2478A), which consists in the fact that the strain is non-. identified asporogenic
    Actinomycete 907-21 ATCC 39417 is cultivated in a liquid nutrient medium containing sources of carbon and nitrogen and Mi-sheral salts under deep aerobic conditions at 27-32 ° C,
    the culture broth and mycelium are separated, the mycelium is extracted with methanol, and the culture broth is separated with butanol, the obtained extracts containing the antibiotic complex are bulked and subjected to chromatographic purification, then the resulting target product is passed through a chromatographic column, eluted with a mixture of chloroform and methanol the increasing concentration of the latter is from 5 to 10% and the antibiotic BBM-2478B is isolated when the content of methanol in the eluting mixture is 5%, and the anti-biotic BBM-2478A - at 10%.
    The minimum inhibitory concentration. radio (MIC), µg 1 ml
    BBM-2478A
    one
    BBM-2478B
    3.1 6.3
    0.8
    3.1
    1.6
    100
    100; -1.00
    Microorganism type
    Minimum inhibitory concentration (mc), µg 1 ml
    BBM-2478A
    Asperglllus fumigatus
    LAM 2530
    Trichophyton mentag
    rophytes D155
    Bacteroides fragllis Clostridium difficile Clostridium perfringens Propionobacteriian acnes
    I
    BBM-2478B
    100
    100
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining glycoside antibiotics VVM-2478A and VVM-2478V antibiotic complex VVM-2478
    OR (antibiotic VVM-2478A), consisting in the fact that the strain of non-identified asporogenous actinomycete T 907-21 ATCC 39417 is cultivated in a liquid nutrient medium containing carbon and nitrogen sources and mineral salts, under deep aerobic conditions at 27-32 ° C, then the culture broth and mycelium are separated, the mycelium is extracted with methanol, and the culture broth with butanol, the obtained extracts containing the antibiotic complex are combined and chromatographed, then the target product obtained is passed through chromatographic column, elute with a mixture of chloroform and methanol at an increasing concentration of the latter from 5 to 107. and isolate the antibiotic BBM-2478B with a methanol content of the elution mixture 5Z, and antibiotic BBM-2478A at 10Z.
    Type of microorganism Minimum inhibitory concentration, walkie-talkie (MIC), mcg 1 mlVVM-2478A VVM-2478V
    Staphylococcus aureus 209p
    Staphylococcus aureus
    Smith
    Bacillus subtilis
    PCT 219
    Micrococcus luteus
    PCT 1001
    Micrococcus flavus D12
    Escherichia coli NIHJ
    Klebsiella pneumoniae dll
    Pseudomonas aeruginosa DI 5
    Candida albicans
    Iam 4888
    Cryptococcus neoformans D49
    1,6 3,1 0.8 6.3 0.8 0.8 0.8 3,1 0.8 1,6 100 > 100 100 > yo 100 > 100 > 100 > 100 > 100 > 100
    Type of microorganism
    Table continuation
    Minimum Inhibitory Concentration (MIC), mcg 1 ml
    VVM-2478A
    VVM-2478V
    Aspergillus fumigatue
    LAM 2530 > 100 > 100 Trichophyton mentagrophytes D155 > 100 > 100 Bacteroides fragilis 12.5 - Clostridium difficile 12.5 - Clostridium perfringens 6.3 - Propionobacterium acnes 6.3 -
    fiftyCompiled by G. Smirnov Editor And Mountain Tehred L. Serdyukova Corrector L. Pilipenko
    Order 4444/59 Circulation 520 Subscription
    VNIIIPI of the USSR State Committee for Inventions and Discoveries 113035, Moscow, Zh-35, Raushskaya nab., 4/5
    Production and printing company, Uzhhorod, st. Project, 4
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1423001A3|1988-09-07|Method of producing glycoside antibiotics bbm-2478a and bbm-2478b of antibiotic complex bbm-2478
    Tanaka et al.1975|Nanaomycins, new antibiotics produced by a strain of Streptomyces I. taxonomy, isolation, characterization and biological properties
    US4107297A|1978-08-15|Antibiotic compound
    WO1987006265A1|1987-10-22|Novel compounds dc-88a and dc-89a1 and process for their preparation
    US4328316A|1982-05-04|Biologically pure culture of actinoplanes capable of producing antibiotic A/16686
    KR900006233B1|1990-08-27|Process for producing polycyclic ether antibiotics
    FR2569702A1|1986-03-07|NOVEL 4'-DESCHLOROREBECCAMYCIN, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND PROCESS FOR PREPARING THE SAME
    US5081023A|1992-01-14|Antibiotic l53-18a and process for preparation thereof
    HU182267B|1983-12-28|Process for preparing the antibiotic c-15003 p-3
    US4551533A|1985-11-05|Antibiotic LL-D42067α
    US4328211A|1982-05-04|Antibiotic Actinomadura-L-31 A, B
    US4517296A|1985-05-14|Antibiotic acmimycin and its production
    US4540517A|1985-09-10|Antibiotic TAN-420
    US4248863A|1981-02-03|Antibiotics saframycins A, B, C, D and E and process for producing the same
    US4764602A|1988-08-16|Antibiotics, and their production
    US4373028A|1983-02-08|Culture of Nocardia ATCC 31309
    Hayashi et al.1994|NISAMYCIN, A NEW MANUMYCIN GROUP ANTIBIOTIC FROM Streptomyces sp. K106 I. TAXONOMY, FERMENTATION, ISOLATION, PHYSICO-CHEMICAL AND BIOLOGICAL PROPERTIES
    Sato et al.1982|A new antibiotic echinosporin |-producing organism, isolation and characterization
    CA1152915A|1983-08-30|Antibiotics c-14482 b.sub.1, b.sub.2 andb.sub.3
    US3954970A|1976-05-04|Actinomycin complex from micromonospora
    CA1047953A|1979-02-06|Ionomycin from streptomyces conglobatus
    US4774184A|1988-09-27|Culture and process for producing antibiotic LL-D42067alpha
    US5674732A|1997-10-07|Rapamycin producer
    US4572895A|1986-02-25|Process for preparing an antibiotic complex by culturing actinomyces strain ATCC 39417
    US4032631A|1977-06-28|Mixture of antibiotics produced by new species of micromonospora
    同族专利:
    公开号 | 公开日
    DE3436137C2|1993-12-02|
    OA07827A|1986-11-20|
    FI843823A0|1984-09-28|
    IE57825B1|1993-04-21|
    JPS60115599A|1985-06-22|
    ATA313184A|1986-03-15|
    GB8424810D0|1984-11-07|
    LU85572A1|1985-06-19|
    CA1242159A|1988-09-20|
    FI843823L|1985-04-04|
    DK473484A|1985-04-04|
    GB2147582A|1985-05-15|
    GR80551B|1985-02-06|
    ES8602135A1|1985-11-16|
    GB2147582B|1987-04-15|
    PT79310B|1986-11-14|
    CH666043A5|1988-06-30|
    IT8422961D0|1984-10-03|
    SE460481B|1989-10-16|
    SE8404929L|1985-04-04|
    DK473484D0|1984-10-02|
    PT79310A|1984-11-01|
    MX9202848A|1992-06-30|
    IL73126D0|1984-12-31|
    FI79141C|1989-11-10|
    FR2555586B1|1988-10-07|
    FR2555586A1|1985-05-31|
    BE900735A|1985-04-02|
    JPH0566394B2|1993-09-21|
    AU3354884A|1986-09-11|
    HK82790A|1990-10-19|
    HUT37170A|1985-11-28|
    IT1176854B|1987-08-18|
    JPH0641182A|1994-02-15|
    IL73126A|1989-05-15|
    ZA847723B|1985-05-29|
    JPH0689017B2|1994-11-09|
    CY1534A|1990-11-16|
    US4518589A|1985-05-21|
    DE3436137A1|1985-05-15|
    HU192461B|1987-06-29|
    MY101664A|1991-12-31|
    SE8404929D0|1984-10-02|
    IE842511L|1985-04-03|
    NL8403002A|1985-05-01|
    FI79141B|1989-07-31|
    AT381507B|1986-10-27|
    AU570271B2|1988-03-10|
    ES536455A0|1985-11-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4859598A|1984-03-26|1989-08-22|American Cyanamid Company|Antibiotic LL-D42067β|
    US4626503A|1984-04-04|1986-12-02|American Cyanamid Company|Antitumor agents LL-D49194α1, LL-D49194β1, LL-D49194β2, LL-D49194β3, LL-D49194γ, LL-D49194δ, LL-D49194ε, LL-D49194ξ, LL-D49194η, LL-D49194ω1, LL-D49194ω2, and LL-D49194ω3|
    CA1263645A|1984-04-27|1989-12-05|Hideo Sugi|Chartreusin derivatives, salts thereof, antitumorouscompositions containing the same, and processes forproducing the same|
    EP0219852B1|1985-10-23|1992-02-05|Ishihara Sangyo Kaisha, Ltd.|Chartreusin derivatives, salts thereof, antitumorous compositions containing the same, and processes for producing the same|
    DK0381114T3|1989-01-30|1994-10-24|Ishihara Sangyo Kaisha|Exo-3,4-O-benzylidene-3 "demethylchartreusin and its salts|
    IN172911B|1991-02-26|1994-01-01|Hoechst India|
    HU210418B|1991-05-30|1995-04-28|Bristol Myers Squibb Co|Process for prepg. 2"-n-acyl derivs of elsamycin a and pharmaceutical compositions containing them|
    HU210499B|1991-05-30|1995-04-28|Bristol Myers Squibb Co|Process for preparing 6-o-alkylelsamicin a deriv.s and pharmaceutical compn.s contg. them|
    ZA923815B|1991-05-30|1993-02-24|Squibb Bristol Myers Co|Preparation of 6-o-acylelsamicin a derivatives|
    HU210162B|1991-05-30|1995-02-28|Bristol Myers Squibb Co|Process for preparing 3',4'-o-substituted elsamicin a deriv.s and pharmaceutical compn.s contg. them|
    US5229371A|1991-05-30|1993-07-20|Bristol-Myers Squibb Company|Chemical modification of elsamicin A at the 3' and/or 4' OH groups|
    US5237055A|1991-05-30|1993-08-17|Bristol-Myers Squibb Company|Chemical modification of 2"-amino group in elsamicin A|
    US5508268A|1993-08-12|1996-04-16|Bristol-Myers Squibb|Parenteral elsamitrucin formulations|
    WO2008092103A2|2007-01-25|2008-07-31|Spectrum Pharmaceuticals, Inc.|Combination cancer treatments comprising elsamitrucin and other agents|
    CN101472938A|2007-05-24|2009-07-01|癌症治疗公司|Stable yisaluser salt suitable for medicament preparation|
    AU2008342992A1|2007-12-19|2009-07-09|Spectrum Pharmaceuticals, Inc.|Stable elsamitrucin salt formulations|
    JP2009207970A|2008-03-03|2009-09-17|Marsima Aqua System Corp|Air lift device|
    CN111751469A|2020-07-06|2020-10-09|江苏省中医院|Method for measuring concentration of tebucin in plasma by liquid chromatography tandem mass spectrometry|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/538,453|US4518589A|1983-10-03|1983-10-03|BBM-2478 Antibiotic complex|
    [返回顶部]